Business Segment (Tables)

3 Months Ended

Mar. 31, 2025

Segment Reporting [Abstract]

Schedule of Segment Reporting Information

The table below is a summary of the segment net loss, including significant segment expenses (in millions):

	Three Months Ended March 31,
	2025		2024
Total revenues	28		145
Less:
Late-stage development programs (1)	55		63
Early-stage development and preclinical programs (2)	42		25
Compensation and personnel costs	66		64
Depreciation and amortization	3		3
Impairment of long-lived assets	—		20
Interest income, net	(10)		(12)
Income tax expense	—		—
Other segment items (3)	22		23
Partnership reimbursements	(38)		(37)
Segment net loss and Consolidated net loss	$	(112)	$	(4)

(1) R&D expenses incurred related to a Phase 3 clinical program intended to result in registration of a new product. This includes all unallocated program-level expense not directly attributable to a specific clinical trial once a molecule enters into one or more Phase 3 clinical trials.

(2) R&D expenses incurred for activities ranging from early-stage development and preclinical to Phase 2 clinical trials. This includes all unallocated program-level expense not directly attributable to a specific clinical trial unless the related program has entered into one or more Phase 3 clinical trials..

(3) Other segment items includes non-allocated program costs and other G&A costs.